Application of substance for inhibiting phosphorylation of 357 tyrosine residue of YAP protein to prevention of atherosclerosisA technology of atherosclerosis and tyrosine residues, applied in the field of biomedicine, can solve the problem that the signal transduction mechanism is not clearly explained
Active Publication Date: 2019-11-05TIANJIN MEDICAL UNIVView PDF5 Cites 1 Cited by - Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
However, the specific signal transduction mechanism has not been elucidated clearly Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine View moreImage
Smart Image Click on the blue labels to locate them in the text.Viewing ExamplesSmart Image
Examples
Experimental program Comparison scheme Effect test Embodiment 1
[0030] Example 1, Src / c-Abl dual inhibitor inhibits activation of vascular endothelial cells
[0031] Both Nilotinib and Bosutinib are Src / c-Abl dual inhibitors, and Bosutinib is the third-generation Src / c-Abl dual inhibitor.
[0032] 1. Src / c-Abl dual inhibitor significantly affects YAP tyrosine phosphorylation
[0033] 1. Take the cell plate, add fibronectin, and incubate overnight at 4°C.
[0034] 2. After completing step 1, take the cell plate, discard fibronectin, and inoculate 3×10 6 HUVECs, and then add Nilotinib-containing DMSO solution or Bosutinib-containing DMSO solution to obtain a treatment system. In the treatment system, the concentration of Nilotinib or Bosutinib was 10 μM.
[0035] 3. After completing step 1, take the cell plate, discard fibronectin, and inoculate 3×10 6 HUVECs, then add DMSO (equal volume to the DMSO solution containing Nilotinib in step 2) to obtain a treatment system (as a control).
[0036] 4. After completing steps 2 and 3, take the tr...
Embodiment 2
[0050] Example 2, p-YAP Y357 and p-c-Abl Y412 Important role in vascular endothelial cell activation and plaque formation
[0051] 1. Detection of p-c-Abl in mouse vascular arch Y412 and p-YAP Y357 expression level of
[0052] 1. Take 6-8 weeks old ApoE respectively - / - The vascular arches (bifurcation and lnner) of mice are prone to atherosclerosis, and the blood flow is turbulent, referred to as AA) and the straight part of the blood vessel (the In the protected area, the form of blood flow is laminar flow, referred to as TA).
[0053] 2. After completing step 1, perform immunofluorescence staining to determine the phosphorylation levels of YAP and c-Abl.
[0054] For the experimental results of the phosphorylation level of YAP tyrosine 357, see figure 2 Middle A (green fluorescently labeled p-YAP Y357 , red fluorescent marker CD31 (endothelial cell marker), blue marker nuclei (DAPI), the scale bar is 80 μm, n=6, merge is superposition effect). The experimental res...
Embodiment 3
[0062] Example 3, Bosutinib slows diet and partial ligation-induced atherosclerosis
[0063] Western Diet is a product of Research Diets, Inc., catalog number D12109C.
[0064] 1. Bosutinib slows down diet-induced atherosclerosis
[0065]To further verify the role of tyrosine kinase-mediated YAP phosphorylation in promoting atherosclerotic phenotype in vascular endothelial cells, the inventors of the present invention conducted the following experiments.
[0066] 1. Take 11 6-week-old ApoE mice - / - The mice were randomly divided into an experimental group and a control group, with 5 mice in the experimental group and 6 mice in the control group. Do the following:
[0067] Experimental group: DMSO solution containing Bosutinib was injected intraperitoneally one week before the experiment, with a dose of 30 mg Bosutinib / kg per injection, once every two days for 5 weeks; from the second week, Western diet was added for 4 weeks.
[0068] Control group: The same volume of DMSO ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine Login to view more PUM
Login to view more Abstract
The invention discloses application of a substance for inhibiting phosphorylation of a 357 tyrosine residue of a YAP protein to prevention of atherosclerosis. The substance for inhibiting phosphorylation of the 357 tyrosine residue of the YAP protein is an Src / c-Abl tyrosine kinase double inhibitor or a c-Abl inhibitor or an Src inhibitor; bosutinib is adopted as the Src / c-Abl tyrosine kinase double inhibitor; and experiments prove that the bosutinib prevents atherosclerosis, treats atherosclerosis, decreases the area of plaques of atherosclerosis, reduces lipid deposition, decreases the collagen content, inhibits forming of the plaques of atherosclerosis, inhibits activation of vascular endothelial cells and inhibits the expression level of adherence factors by inhibiting phosphorylation of the 357 tyrosine residue of the YAP protein. The substance has significant application value.Description
technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of a substance inhibiting phosphorylation of the 357th tyrosine residue of YAP protein in preventing atherosclerosis. Background technique [0002] Atherosclerosis is the main cause of acute myocardial infarction and stroke, which brings great harm to human health and economic burden. Activation of vascular endothelial cells is the initiating factor of atherosclerosis formation. Endothelial cells can sense a variety of chemical signals (such as TNFα and LPS) and physical stimuli (such as blood flow shear force). Once the vascular endothelial cells are activated, the inflammatory response is triggered, mainly up-regulating the expression levels of adhesion factors ICAM-1 and VCAM-1. Because blood is flooding in blood vessels, vascular endothelial cells continue to sense changes in the state of blood flow, atherosclerotic plaques often occur at the bifurcati...Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine Login to view more Application Information
Patent Timeline 
Login to view more Patent Type & Authority Applications(China)IPC IPC(8): A61K45/00A61K31/506A61K31/496A61P9/10G01N33/68CPCA61K31/496A61K31/506A61K45/00A61P9/10G01N33/6893G01N2800/323G01N2800/50 Inventor 朱毅艾玎李博川何金龙 Owner TIANJIN MEDICAL UNIVWho we serve- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media Try Eureka Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap
A technology of atherosclerosis and tyrosine residues, applied in the field of biomedicine, can solve the problem that the signal transduction mechanism is not clearly explained
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0030] Example 1, Src / c-Abl dual inhibitor inhibits activation of vascular endothelial cells
[0031] Both Nilotinib and Bosutinib are Src / c-Abl dual inhibitors, and Bosutinib is the third-generation Src / c-Abl dual inhibitor.
[0032] 1. Src / c-Abl dual inhibitor significantly affects YAP tyrosine phosphorylation
[0033] 1. Take the cell plate, add fibronectin, and incubate overnight at 4°C.
[0034] 2. After completing step 1, take the cell plate, discard fibronectin, and inoculate 3×10 6 HUVECs, and then add Nilotinib-containing DMSO solution or Bosutinib-containing DMSO solution to obtain a treatment system. In the treatment system, the concentration of Nilotinib or Bosutinib was 10 μM.
[0035] 3. After completing step 1, take the cell plate, discard fibronectin, and inoculate 3×10 6 HUVECs, then add DMSO (equal volume to the DMSO solution containing Nilotinib in step 2) to obtain a treatment system (as a control).
[0036] 4. After completing steps 2 and 3, take the tr...
Embodiment 2
[0050] Example 2, p-YAP Y357 and p-c-Abl Y412 Important role in vascular endothelial cell activation and plaque formation
[0051] 1. Detection of p-c-Abl in mouse vascular arch Y412 and p-YAP Y357 expression level of
[0052] 1. Take 6-8 weeks old ApoE respectively - / - The vascular arches (bifurcation and lnner) of mice are prone to atherosclerosis, and the blood flow is turbulent, referred to as AA) and the straight part of the blood vessel (the In the protected area, the form of blood flow is laminar flow, referred to as TA).
[0053] 2. After completing step 1, perform immunofluorescence staining to determine the phosphorylation levels of YAP and c-Abl.
[0054] For the experimental results of the phosphorylation level of YAP tyrosine 357, see figure 2 Middle A (green fluorescently labeled p-YAP Y357 , red fluorescent marker CD31 (endothelial cell marker), blue marker nuclei (DAPI), the scale bar is 80 μm, n=6, merge is superposition effect). The experimental res...
Embodiment 3
[0062] Example 3, Bosutinib slows diet and partial ligation-induced atherosclerosis
[0063] Western Diet is a product of Research Diets, Inc., catalog number D12109C.
[0064] 1. Bosutinib slows down diet-induced atherosclerosis
[0065]To further verify the role of tyrosine kinase-mediated YAP phosphorylation in promoting atherosclerotic phenotype in vascular endothelial cells, the inventors of the present invention conducted the following experiments.
[0066] 1. Take 11 6-week-old ApoE mice - / - The mice were randomly divided into an experimental group and a control group, with 5 mice in the experimental group and 6 mice in the control group. Do the following:
[0067] Experimental group: DMSO solution containing Bosutinib was injected intraperitoneally one week before the experiment, with a dose of 30 mg Bosutinib / kg per injection, once every two days for 5 weeks; from the second week, Western diet was added for 4 weeks.
[0068] Control group: The same volume of DMSO ...
PUM
Login to view more Abstract
Description
Claims
Application Information
Login to view more - R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap